10x Genomics $TXG Stock: Inscription Capital LLC Trims Position

Key Points

• Inscription Capital cut its 10x Genomics stake by 65% in the third quarter, selling 33,999 shares and ending the period with 18,323 shares valued at about $1.66 million.
• 10x Genomics beat quarterly expectations, reporting a loss of $0.15 per share and $150.7 million in revenue, though sales grew just 1.1% year over year. The article also reports the stock was down 14%.
• Analysts’ consensus rating was Hold, with an average price target of $68; company insiders also sold 179,333 shares worth about $11.8 million over the prior quarter.

Inscription Capital LLC decreased its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 65.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 18,323 shares of the company's stock after selling 33,999 shares during the period. Inscription Capital LLC's holdings in 10x Genomics were worth $1,656,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its stake in 10x Genomics by 29.9% in the third quarter. Farther Finance Advisors LLC now owns 934 shares of the company's stock worth $84,000 after purchasing an additional 215 shares during the period. GAMMA Investing LLC boosted its position in shares of 10x Genomics by 8.7% in the 3rd quarter. GAMMA Investing LLC now owns 4,668 shares of the company's stock worth $422,000 after purchasing an additional 374 shares in the last quarter. Arizona State Retirement System boosted its position in shares of 10x Genomics by 1.5% in the 2nd quarter. Arizona State Retirement System now owns 29,223 shares of the company's stock worth $1,120,000 after purchasing an additional 430 shares in the last quarter. Carolina Wealth Advisors LLC purchased a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $46,000. Finally, Nisa Investment Advisors LLC grew its stake in shares of 10x Genomics by 11.7% in the 3rd quarter. Nisa Investment Advisors LLC now owns 6,239 shares of the company's stock worth $564,000 after buying an additional 653 shares during the last quarter. Institutional investors own 84.68% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Stifel Nicolaus set a $70.00 price objective on 10x Genomics in a research note on Tuesday, October 13th. Barclays upped their target price on shares of 10x Genomics from $52.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 7th. UBS Group assumed coverage on shares of 10x Genomics in a report on Wednesday, September 9th. They set a "neutral" rating and a $68.00 price target on the stock. Leerink Partners raised their price target on shares of 10x Genomics from $40.00 to $90.00 and gave the company a "market perform" rating in a research report on Tuesday, September 29th. Finally, Morgan Stanley upped their price objective on 10x Genomics from $40.00 to $70.00 and gave the company an "equal weight" rating in a research report on Monday, October 12th. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $68.00.

Insider Buying and Selling at 10x Genomics

In other news, Director Shehnaaz Suliman sold 5,723 shares of the company's stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total value of $464,650.37. Following the completion of the transaction, the director owned 23,792 shares of the company's stock, valued at $1,931,672.48. This represents a 19.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Adam Taich sold 46,388 shares of the business's stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the completion of the transaction, the chief financial officer directly owned 316,344 shares in the company, valued at approximately $20,426,332.08. This represents a 12.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is currently owned by corporate insiders.

10x Genomics Stock Down 14.0%

10x Genomics stock opened at $58.06 on Friday. 10x Genomics has a 52-week low of $12.80 and a 52-week high of $102.81. The company has a market cap of $7.56 billion, a P/E ratio of -98.41 and a beta of 2.03. The business has a 50-day simple moving average of $74.06 and a two-hundred day simple moving average of $41.41.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.12. The firm had revenue of $150.67 million during the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. 10x Genomics's revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.22) EPS. Research analysts anticipate that 10x Genomics will post -0.77 EPS for the current fiscal year.

Key Headlines Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q3 revenue was $150.7 million, above the roughly $148 million consensus, while the loss of $0.15 per share was narrower than analysts’ expected loss of $0.27. Revenue increased 1.1% year over year. Article: 10x Genomics Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: The company forecast 2026 revenue of $625 million to $635 million and said it is targeting about 50 Atera shipments by year-end, providing a revenue outlook and a near-term product milestone. Article: 10x Genomics Forecasts 2026 Revenue and Atera Shipments
• Neutral Sentiment: Broader technology stocks were volatile, with a report noting a sharp Nasdaq decline followed by a bounce. That market backdrop may have added uncertainty, but the article does not identify a TXG-specific effect. Article: Dow Jones Futures Fall, Techs Bounce
• Negative Sentiment: Despite the earnings beats, TXG declined after the results. The quarter still showed only 1.1% year-over-year revenue growth and a net loss, which may have tempered investor enthusiasm. Article: Q3 Sales Top Estimates but Stock Drops

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company's product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.